SynthesisJournal of nephrology2025
Biopsy-proven glomerular diseases: a systematic review of global kidney biopsy registries.
Synthesis in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence-powered renal pathology for glomerular disease classification: a systematic review and meta-analysis.Renal failure · 2026Pooled it
- From fundus to filtration: AI-driven retinal phenotyping as a framework for non-invasive prediction of kidney pathological categories (the "virtual renal biopsy" concept)- a narrative review.International urology and nephrology · 2026Review
- [Approach to suspected glomerulonephritis].Innere Medizin (Heidelberg, Germany) · 2026Review
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlomerular diseases are a major contributor to chronic kidney disease (CKD) and kidney failure worldwide. The prevalence and spectrum of these diseases vary substantially across geographic regions, reflecting differences in genetic predisposition, environmental exposures, and healthcare practices. Although numerous kidney biopsy registries have been established globally, synthesizing their findings is required. The present systematic review aimed to integrate data from national and regional kidney biopsy registries to evaluate the global distribution of biopsy-proven glomerular diseases.
methodsA comprehensive search was performed using MEDLINE, Embase, Scopus, Cochrane Library, and Google Scholar databases. Studies were eligible if they reported original data from kidney biopsy registries in adult patients undergoing native kidney biopsy, with histopathological diagnoses of primary or secondary glomerulonephritis.
resultsThirty-nine studies met the inclusion criteria. IgA nephropathy was the most common primary glomerular disease worldwide, with exceptionally high prevalence in East Asia (up to 35.8%) and moderate prevalence in Europe (up to 20%). Membranous nephropathy and focal segmental glomerulosclerosis showed marked regional variability, with focal segmental glomerulosclerosis predominating in North and South America (over 20%). Among secondary glomerular diseases, lupus nephritis was more prevalent in South America, diabetic nephropathy in North America, and vasculitis-related glomerulonephritis in Europe and North America, with lower rates in Asia.
conclusionsOur findings support the critical role of biopsy registries in nephrology research and emphasize the need for international harmonization of biopsy protocols and diagnostic standards. Integrating histological, clinical, and molecular data constitutes a key step to advancing precision nephrology globally.
Indexed as
Identifiers
41217595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.